113 related articles for article (PubMed ID: 12699380)
41. Combinatorial QSAR modeling of specificity and subtype selectivity of ligands binding to serotonin receptors 5HT1E and 5HT1F.
Wang XS; Tang H; Golbraikh A; Tropsha A
J Chem Inf Model; 2008 May; 48(5):997-1013. PubMed ID: 18470978
[TBL] [Abstract][Full Text] [Related]
42. The importance of local chemical structure for chemical metabolism by human uridine 5'-diphosphate-glucuronosyltransferase.
Sorich MJ; McKinnon RA; Miners JO; Smith PA
J Chem Inf Model; 2006; 46(6):2692-7. PubMed ID: 17125209
[TBL] [Abstract][Full Text] [Related]
43. Quantitative structure activity relationships in drug metabolism.
Chohan KK; Paine SW; Waters NJ
Curr Top Med Chem; 2006; 6(15):1569-78. PubMed ID: 16918469
[TBL] [Abstract][Full Text] [Related]
44. Ligand-based assessment of factor Xa binding site flexibility via elaborate pharmacophore exploration and genetic algorithm-based QSAR modeling.
Taha MO; Qandil AM; Zaki DD; AlDamen MA
Eur J Med Chem; 2005 Jul; 40(7):701-27. PubMed ID: 15935905
[TBL] [Abstract][Full Text] [Related]
45. 4D-QSAR analysis of a series of antifungal p450 inhibitors and 3D-pharmacophore comparisons as a function of alignment.
Liu J; Pan D; Tseng Y; Hopfinger AJ
J Chem Inf Comput Sci; 2003; 43(6):2170-9. PubMed ID: 14632469
[TBL] [Abstract][Full Text] [Related]
46. Pharmacophore, 3D-QSAR Models and Dynamic Simulation of 1,4-Benzothiazines for Colorectal Cancer Treatment.
Rai A; Raj V; Aboumanei MH; Singh AK; Keshari AK; Verma SP; Saha S
Comb Chem High Throughput Screen; 2017; 20(8):658-674. PubMed ID: 28486913
[TBL] [Abstract][Full Text] [Related]
47. Metabolism of 1'- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7.
Seo KA; Bae SK; Choi YK; Choi CS; Liu KH; Shin JG
Drug Metab Dispos; 2010 Nov; 38(11):2007-13. PubMed ID: 20713656
[TBL] [Abstract][Full Text] [Related]
48. A comparison of methods for pharmacophore generation with the catalyst software and their use for 3D-QSAR: application to a set of 4-aminopyridine thrombin inhibitors.
Greenidge PA; Weiser J
Mini Rev Med Chem; 2001 May; 1(1):79-87. PubMed ID: 12369993
[TBL] [Abstract][Full Text] [Related]
49. Influence of N-terminal domain histidine and proline residues on the substrate selectivities of human UDP-glucuronosyltransferase 1A1, 1A6, 1A9, 2B7, and 2B10.
Kerdpin O; Mackenzie PI; Bowalgaha K; Finel M; Miners JO
Drug Metab Dispos; 2009 Sep; 37(9):1948-55. PubMed ID: 19487247
[TBL] [Abstract][Full Text] [Related]
50. Prediction of Novel Anoctamin1 (ANO1) Inhibitors Using 3D-QSAR Pharmacophore Modeling and Molecular Docking.
Lee YH; Yi GS
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30336555
[TBL] [Abstract][Full Text] [Related]
51. Kinetic modeling of the interactions between 4-methylumbelliferone, 1-naphthol, and zidovudine glucuronidation by udp-glucuronosyltransferase 2B7 (UGT2B7) provides evidence for multiple substrate binding and effector sites.
Uchaipichat V; Galetin A; Houston JB; Mackenzie PI; Williams JA; Miners JO
Mol Pharmacol; 2008 Oct; 74(4):1152-62. PubMed ID: 18647858
[TBL] [Abstract][Full Text] [Related]
52. Human UDP-glucuronosyltransferase (UGT) 2B10 in drug N-glucuronidation: substrate screening and comparison with UGT1A3 and UGT1A4.
Kato Y; Izukawa T; Oda S; Fukami T; Finel M; Yokoi T; Nakajima M
Drug Metab Dispos; 2013 Jul; 41(7):1389-97. PubMed ID: 23611809
[TBL] [Abstract][Full Text] [Related]
53. Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques.
Roy K; Pratim Roy P
Eur J Med Chem; 2009 Jul; 44(7):2913-22. PubMed ID: 19128860
[TBL] [Abstract][Full Text] [Related]
54. Morphine glucuronidation and glucosidation represent complementary metabolic pathways that are both catalyzed by UDP-glucuronosyltransferase 2B7: kinetic, inhibition, and molecular modeling studies.
Chau N; Elliot DJ; Lewis BC; Burns K; Johnston MR; Mackenzie PI; Miners JO
J Pharmacol Exp Ther; 2014 Apr; 349(1):126-37. PubMed ID: 24459244
[TBL] [Abstract][Full Text] [Related]
55. Evidence for overlapping active sites for 17 alpha-ethynlestradiol and bilirubin in the human major bilirubin UDPglucuronosyltransferase.
Ciotti M; Owens IS
Biochemistry; 1996 Aug; 35(31):10119-24. PubMed ID: 8756475
[TBL] [Abstract][Full Text] [Related]
56. Conjugation of catechols by recombinant human sulfotransferases, UDP-glucuronosyltransferases, and soluble catechol O-methyltransferase: structure-conjugation relationships and predictive models.
Taskinen J; Ethell BT; Pihlavisto P; Hood AM; Burchell B; Coughtrie MW
Drug Metab Dispos; 2003 Sep; 31(9):1187-97. PubMed ID: 12920175
[TBL] [Abstract][Full Text] [Related]
57. Substrate specificity of human hepatic udp-glucuronosyltransferases.
Burchell B; Lockley DJ; Staines A; Uesawa Y; Coughtrie MW
Methods Enzymol; 2005; 400():46-57. PubMed ID: 16399342
[TBL] [Abstract][Full Text] [Related]
58. A Structure-Activity Relationship Study of Naphthoquinone Derivatives as Antitubercular Agents Using Molecular Modeling Techniques.
Sharma MC
Interdiscip Sci; 2015 Dec; 7(4):346-56. PubMed ID: 26159131
[TBL] [Abstract][Full Text] [Related]
59. A recombinant phenobarbital-inducible rat liver UDP-glucuronosyltransferase (UDP-glucuronosyltransferase 2B1) stably expressed in V79 cells catalyzes the glucuronidation of morphine, phenols, and carboxylic acids.
Pritchard M; Fournel-Gigleux S; Siest G; Mackenzie P; Magdalou J
Mol Pharmacol; 1994 Jan; 45(1):42-50. PubMed ID: 8302279
[TBL] [Abstract][Full Text] [Related]
60. Quaternary ammonium-linked glucuronidation of 1-substituted imidazoles: studies of human UDP-glucuronosyltransferases involved and substrate specificities.
Vashishtha SC; Hawes EM; McKay G; McCann DJ
Drug Metab Dispos; 2001 Oct; 29(10):1290-5. PubMed ID: 11560872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
